Xenon Pauses Phase 3 Depression Trials After Adverse Neuropsychiatric Events
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Xenon has voluntarily stopped enrolling new patients in its phase 3 depression trials due to reports of adverse events. The company noted that these events were mostly mild or moderate in nature.
The occurrence of “neuropsychiatric” adverse events in testing has led to a decline in Xenon's shares following the trial pause.
Xenon
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — Xenon shares fall following depression trial pause“The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events.”
fierce biotech — <a href="/biotech/xenon-pauses-phase-3-depression-trials-after-psychosis-events" hreflang="en">Xenon pauses phase 3 depression trials after psychosis events</a>